M C Klee1, M T King, D Machin, H H Hansen. 1. Department of Oncology, Finsencenter, Rigshospitalet, Copenhagen, Denmark. kleeo@dadlnet.dk
Abstract
BACKGROUND: The pattern of symptoms experienced by cancer patients during chemotherapy is very complex. Consequently, quality of life (QOL) assessment has to be carefully planned to capture clinically relevant changes. PATIENTS AND METHODS: A clinical model of changes in symptoms experienced by symptomatic metastatic patients during several courses of chemotherapy has been developed. The model differentiates cancer-related symptoms, acute side-effects, chronic side-effects and symptoms not related to cancer. The model was used to predict changes in each of these four symptom groups. Three time points were selected (post-cycle 2, pre-cycle 3, post-cycle 5) and an appropriate window around each time point was set. The model predictions were tested empirically with 56 patients with advanced ovarian cancer who completed the EORTC QLQ-C30 plus disease specific items during a six-cycle course of chemotherapy. RESULTS: The changes observed in the sample were in accordance with the changes predicted by the clinical model. Results from patients who did not complete the questionnaire within the specified time windows tended to dilute the findings from the group who did. CONCLUSIONS: A clinical model is useful in the planning of QOL assessments in order to capture clinically relevant effects. Such models also facilitate the interpretation of QOL studies, particularly when cyclic short-term effects and chronic side-effects are overlaid on disease symptoms, as is the case with chemotherapy for cancer.
BACKGROUND: The pattern of symptoms experienced by cancerpatients during chemotherapy is very complex. Consequently, quality of life (QOL) assessment has to be carefully planned to capture clinically relevant changes. PATIENTS AND METHODS: A clinical model of changes in symptoms experienced by symptomatic metastatic patients during several courses of chemotherapy has been developed. The model differentiates cancer-related symptoms, acute side-effects, chronic side-effects and symptoms not related to cancer. The model was used to predict changes in each of these four symptom groups. Three time points were selected (post-cycle 2, pre-cycle 3, post-cycle 5) and an appropriate window around each time point was set. The model predictions were tested empirically with 56 patients with advanced ovarian cancer who completed the EORTCQLQ-C30 plus disease specific items during a six-cycle course of chemotherapy. RESULTS: The changes observed in the sample were in accordance with the changes predicted by the clinical model. Results from patients who did not complete the questionnaire within the specified time windows tended to dilute the findings from the group who did. CONCLUSIONS: A clinical model is useful in the planning of QOL assessments in order to capture clinically relevant effects. Such models also facilitate the interpretation of QOL studies, particularly when cyclic short-term effects and chronic side-effects are overlaid on disease symptoms, as is the case with chemotherapy for cancer.
Authors: D E Ediebah; C Coens; J T Maringwa; C Quinten; E Zikos; J Ringash; M King; C Gotay; H-H Flechtner; J Schmucker von Koch; J Weis; E F Smit; C-H Köhne; A Bottomley Journal: Ann Oncol Date: 2012-08-30 Impact factor: 32.976
Authors: Linda Dirven; Jacob C Reijneveld; Neil K Aaronson; Andrew Bottomley; Bernard M J Uitdehaag; Martin J B Taphoorn Journal: Curr Neurol Neurosci Rep Date: 2013-07 Impact factor: 5.081
Authors: Madeleine T King; David Cella; David Osoba; Martin Stockler; David Eton; Joanna Thompson; Amy Eisenstein Journal: Patient Relat Outcome Meas Date: 2010-09-23
Authors: Abdel W Awadalla; Jude U Ohaeri; Abdullah Gholoum; Ahmed O A Khalid; Hussein M A Hamad; Anila Jacob Journal: BMC Cancer Date: 2007-06-19 Impact factor: 4.430
Authors: Johannes M Giesinger; Lisa M Wintner; August Zabernigg; Eva-Maria Gamper; Anne S Oberguggenberger; Monika J Sztankay; Georg Kemmler; Bernhard Holzner Journal: BMC Cancer Date: 2014-10-10 Impact factor: 4.430
Authors: Lene Kongsgaard Nielsen; Madeleine King; Sören Möller; Mary Jarden; Christen Lykkegaard Andersen; Henrik Frederiksen; Henrik Gregersen; Anja Klostergaard; Morten Saaby Steffensen; Per Trøllund Pedersen; Maja Hinge; Mikael Frederiksen; Bo Amdi Jensen; Carsten Helleberg; Anne Kærsgaard Mylin; Niels Abildgaard Journal: Qual Life Res Date: 2019-09-23 Impact factor: 4.147